Cutler Group’s Alder Biopharmaceuticals ALDR Stock Holding History

Cutler Group’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-28,600	Closed	-$2K	–	5674
2017 Q4	$2K	Sell	28,600 -4,700	-14%	-$52.5K	﹤0.01%	4300
2017 Q3	$24K	Sell	33,300 -10,400	-24%	-$108K	﹤0.01%	2982
2017 Q2	$3K	Buy	43,700 +35,200	+414%	+$651K	﹤0.01%	5391
2017 Q1	$2K	Buy	+8,500	New	+$188K	﹤0.01%	5664
2016 Q4	–	Sell	-30,500	Closed	-$34K	–	7735
2016 Q3	$34K	Buy	30,500 +9,300	+44%	+$283K	﹤0.01%	2875
2016 Q2	$18K	Sell	21,200 -37,400	-64%	-$1.01M	﹤0.01%	3507
2016 Q1	$93K	Buy	58,600 +27,900	+91%	+$646K	0.01%	1691
2015 Q4	$94K	Buy	+30,700	New	+$1.04M	0.01%	1837

Cutler Group's ALDR Position: Q4 2019 in Review

Cutler Group sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 1,500 shares — an estimated $28K sold.

Cutler Group first reported a position in ALDR in Q4 2015 and held it in 11 quarters. The position peaked at $492K in Q2 2017. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

Cutler Group reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
Cutler Group sold 1,500 Alder Biopharmaceuticals shares in Q4 2019, an estimated $28K.
Cutler Group first reported a position in Alder Biopharmaceuticals in Q4 2015 and held it in 11 quarters.
Cutler Group's Alder Biopharmaceuticals position peaked at $492K in Q2 2017.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Cutler Group's 13F filing for Q4 2019, filed 6 Feb 2020.